去纤维钠在医保范围内吗？

(Defitelio) was approved by the U.S. FDA on March 30, 2016 for the treatment of hepatic veno-occlusive disease (VOD), also known as sinusoidal obstructive syndrome (SOS), renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT) in adult and pediatric patients. The launch of this drug has also provided great help in the treatment of many patients with hepatic veno-occlusive disease.

However, it is regrettable that defibrinated sodium has not yet been approved for marketing in China, so it cannot be included in the scope of medical insurance. This means that patients can currently only purchase this drug through other channels. It is understood that a box of 200mg defibrinated sodium sells for around $21,600. Due to exchange rate fluctuations, drug prices will change, so you need to consult Medical Companions for specific prices. At the same time, if patients need it, they can also contact Medical Companion Travel to obtain their drug purchase channels, allowing patients to obtain the drugs they need more conveniently.

Using defibrinated sodium to treat hepatic veno-occlusive disease can inhibit the occurrence of apoptosis of vascular endothelial cells, inhibit immune effector cells from entering tissues through endothelial cells, and reduce the occurrence of inflammatory damage. Defibrotide sodium (defibrotide) has been shown to downregulate the expression of cell adhesion molecules CAMs, which are related to inflammatory responses and hematopoietic stem cell mobilization. There are many new blood vessels around the tumor tissue, and defibrinated sodium has anti-neovascularization effect, which is considered to be the basis of its anti-tumor effect.

Studies have shown that defibrinated sodium affects the stability and regeneration of vascular endothelium by affecting the production of anti-angiogenic peptides. Defibrinated sodium shows complex pharmacokinetic characteristics for different vascular tissues. In vitro experiments have shown that it can improve the chemotherapy sensitivity of tumor cells, which indicates that this drug has broad prospects for anti-tumor treatment.

Recommended hot articles: /newsDetail/78601.html